Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil

Othman Al-Sawaf • 14 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies Chlorambucil Obinutuzumab Venetoclax
CLL14

Othman Al-Sawaf, MD, of the University Hospital of Cologne, Cologne, Germany, discusses efficacy and safety results from the multicenter, open-label, randomized Phase III CLL14 study (NCT02242942) investigating the efficacy and safety of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Othman Al-Sawaf

1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023
1:43
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 16 Jun 2023

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals